Lack Of Cost-Effectiveness Analysis For Products In Development Could Affect Company Valuations, Attorney Mahinka Says
Executive Summary
With payers playing a more prominent role in determining access to drugs, developers will need to focus more on the comparative value of a drug throughout the development cycle, including cost. That value equation also will become an important part of the M&A landscape, attorney Stephen Mahinka says.